Press releases
Lena Biosciences appoints Dr. Eckhard von Keutz to its Business Advisory Board and Science Advisory Board
|
Company in the news
Lena Biosciences featured in
3D Cell Culture Market Report |
Announcements and awards
August, 2024
Lena Biosciences is awarded $1.96 M Phase II SBIR
to develop a "virtual human population" screen for predictive toxicology
which incorporates human genetic variability to isolate:
Lena Biosciences is awarded $1.96 M Phase II SBIR
to develop a "virtual human population" screen for predictive toxicology
which incorporates human genetic variability to isolate:
- Sensitive individuals; early responders to toxicants
- Susceptible individuals who respond adversely to lower doses of toxicants than an "average" human, and
- Vulnerable individuals who respond to toxicants through different dose-dependent mechanisms
Landmark study with PerfusionPal featured in PLoS One:
Drug testing in fully humanized, 3D, perfused breast cancer model |
Lena Biosciences receives over $1.8 M Phase II SBIR grant award to apply its screening platform to toxicity testing of chemicals implicated in neurodegenerative diseases
|
2022 Finalist
Mass Challenge US Early Stage Accelerator |
Lena Biosciences receives $300 K Phase I SBIR grant award to apply its screening platform to drug-induced liver injury
|
Finalist RESI Longevity Pitch Challenge
Therapeutics and Diagnostics, Sept. 2021 |
Lena Biosciences publishes Phase I drug metabolism results with PerfusionPal
|
Interdigitated electrodes on SeedEZ scaffolds monitor cardiomyocyte growth
|
Lena Biosciences receives $252 K Phase I SBIR grant award to apply its screening platform to toxicity testing of agrochemicals
|
Lena Biosciences and SpeciCare, a tumor tissue bank, announce collaboration
|